Kymab Limited - a Sanofi company
Kymab is a biopharmaceutical company using a proprietary transgenic antibody platform, Kymouse, to discover and develop fully human monoclonal antibody drugs. The technology used to design the Kymouse strains originated from the Wellcome Trust Sanger Institute in Cambridge, UK. Kymouse™ has been designed to maximise the diversity of human antibodies produced in response to immunisation. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding that rare drug candidate with best-in-class characteristics.